Current standard of care for advanced ER+ breast cancer is endocrine therapy in combination with CDK4/6 inhibitors and although these treatments have had significant impact on extending progression-free and overall survival, the development of therapy-resistant disease remains an inevitability for many patients. The gene discussed is CDK4; the disease is breast carcinoma.